Analysis uncovers significant associations between somatic mutations and venous thromboembolism rates in cancer patients, suggesting an important link.
Key Points
Somatic mutations in genes CDKN2A, KRAS, PCDH15, and TP53 were linked to increased rates of venous thromboembolism.
Multivariable Cox regressions showed a hazard ratio of 1.62 for CDKN2A, highlighting its significance in VTE risk.
Tumour mutational burden of 20 mutations/Mb and certain mutational signatures indicated lower venous thromboembolism rates.
Identifying these associations may improve clinical risk prediction for venous thromboembolism in cancer patients.